Kyprolis® (carfilzomib) for Injection is a Proteosome inhibitor indicated for the treatment of patients with multiple myeloma.
Licensee | Indication | Royalty |
---|---|---|
Amgen | Multiple Myeloma | 1.5-3.0% |
Partner | Indication | Royalty |
---|---|---|
Spectrum | Oncology | 20% |
RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen given by intramuscular injection for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Licensee | Indication | Royalty |
---|---|---|
Jazz | Oncology | 3-5% |
Licensee | Indication | Royalty |
---|---|---|
Alvogen | Osteoporosis | 25-50% |
Licensee | Indication | Royalty |
---|---|---|
Merck | Pneumococcal disease prevention | low single-digit |
Licensee | Indication | Royalty |
---|---|---|
Serum Institute of India | Pneumococcal disease prevention | low single-digit |
Partner | Indication | Royalty |
---|---|---|
Melinta Therapeutics | Infectious Disease | 2.5% |
Captisol-enabled IV formulation of voriconazole
Partner | Indication | Royalty |
---|---|---|
Alvogen | Infectious Disease | Material sales only |
DUAVEE (conjugated estrogens/bazedoxifene) is a progesterone-free treatment for moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and aids in the prevention of postmenopausal osteoporosis.
Partner | Indication | Royalty |
---|---|---|
Pfizer | Menopause | 0.5-2.5% |
Viviant/Conbriza™ (bazedoxifene) is a synthetic drug that was specifically designed to reduce the risk of osteoporotic fractures, while at the same time protecting breast and uterine tissue.
Partner | Indication | Royalty |
---|---|---|
Pfizer | Osteoporosis | 0.5-2.5% |
NEXTERONE (amiodarone HCl) Premixed Injection is indicated for initiation of treatment and prophylaxis for frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to the therapy.
Partner | Indication | Royalty |
---|---|---|
Baxter | Arrhythmia | Undisclosed |
Captisol-enabled IV formulation of Noxafil
Partner | Indication | Royalty |
---|---|---|
Merck | Infectious Disease | Material sales only |
Partner | Indication | Royalty |
---|---|---|
Sage Therapeutics | CNS | 3% |
Captisol-enabled formulation of Veklury
Partner | Indication | Royalty |
---|---|---|
Gilead Sciences | Infectious Disease | Material sales only |